Immuno-oncologyVeraxa Biotech advances bispecific ADC from Omniab collaborationVeraxa Biotech AG has reported the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222, following achievement of a technical milestone in its alliance with Omniab Inc. The program is moving into its next collaboration phase.